TEL
+ 86-21-6420 0566
CAS NO.951382-34-6
| Объект | Подробнее |
| Химическое название | Eglitazar |
| Номер по CAS | 1000410-20-6 |
| Молекулярная формула | \(C_{22}H_{22}O_5\) |
| Молекулярная масса | 366.41 |
| Молекулярная структура | Eglitazar features a complex structure with multiple rings. It has a central heterocyclic ring system, to which are attached various aromatic and aliphatic substituents. The specific arrangement of these groups is designed to interact with the PPAR receptors. |
| Внешний вид | Likely appears as a solid, but specific appearance details may vary based on its purity and form. |
| Растворимость | Information on solubility is somewhat limited, but like many drugs in this class, it may have limited solubility in water and better solubility in organic solvents, which impacts its formulation into pharmaceutical products. |
| Фармакологический класс | PPAR dual agonist (targets both PPARα and PPARγ) |
| Механизм действия | By binding to and activating PPARα and PPARγ receptors, Eglitazar modulates gene expression related to glucose and lipid metabolism. Activation of PPARα increases fatty acid oxidation and improves lipid profiles. Activation of PPARγ enhances insulin sensitivity in adipose tissue, skeletal muscle, and the liver, leading to improved glucose uptake and utilization. This dual – receptor activation aims to address multiple aspects of the metabolic syndrome associated with type 2 diabetes. |
| Медицинские применения | Тип диабета 2: In clinical trials for the treatment of type 2 diabetes. The goal is to improve glycemic control, as measured by HbA1c levels, and also to have beneficial effects on lipid profiles, potentially reducing the risk of cardiovascular complications often associated with diabetes. |
| Стабильность | Stability data may be limited as it is still in development. However, like most drugs, it is likely to be sensitive to factors such as heat, humidity, and light, which could affect its chemical integrity and potency. |
| Вопросы безопасности | In early – stage clinical trials, potential side effects being monitored include weight gain, which is common with some PPARγ – targeting drugs. There may also be risks related to fluid retention, which could potentially impact cardiovascular function. As with any new drug, there is also a need to monitor for potential liver and kidney toxicity, as well as potential interactions with other medications commonly used in patients with diabetes, such as metformin, sulfonylureas, or insulin. |
Условия использования: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
Фабрика и отгрузка
